Over the last ten years, asymmetric organocatalytic cascade reactions have emerged as a powerful strategy for the synthesis of complex molecules bearing multiple stereogenic centers in a highly stereocontrolled fashion.^[@cit1]^ These one-pot organocatalytic reactions were successfully employed for the creation of cyclohexane ring systems bearing up to six stereocenters.^[@cit2]^ Most of these triple cascade reactions are governed by more common 1,4-/1,4-/1,2 addition sequences. Another important class of addition reactions involving the enantioselective 1,6-addition to control the formation of a remote stereocenter is more challenging and less explored in comparison to the other addition variants.^[@cit3]^ Moreover, organocatalytic cascade reactions using all possible types of addition reactions, *i.e.* 1,4-/1,6-/1,2-addition reactions, are not known so far. Hence we took the challenge to develop a new stereoselective one-pot organocascade sequence using 1,4-/1,6-/1,2-additions ([Scheme 1](#sch1){ref-type="fig"}).

![Enantioselective strategies for the construction of cyclohexane rings bearing multiple stereogenic centers.](c4cc09730k-s1){#sch1}

In addition, the isoxazole core is present in various important naturally occurring and synthetic bioactive molecules ([Fig. 1](#fig1){ref-type="fig"}). For example, compounds **A--D** are β-lactamase-resistant antibiotics,^[@cit4]^ while an isoxazole containing natural product **E** is a powerful neurotoxin, which is used as a brain-lesioning agent.^[@cit5]^ A synthetic androgenic steroid danazol **D** bearing an isoxazole ring suppresses the production of gonadotrophins and also has some weak androgenic effects.^[@cit6]^ Moreover, isoxazoles serve as precursors for the synthesis of various synthetically useful organic compounds.^[@cit7]^ Thus, the development of efficient asymmetric methods for the synthesis of isoxazole ring containing molecules can provide a new series of potentially bioactive molecules.

![Enantiopure drugs and bioactive natural products bearing an isoxazole ring.](c4cc09730k-f1){#fig1}

Recently, organo- and metal-catalyzed 1,6-additions to 4-nitro-5-styrylisoxazoles emerged as an efficient method to generate enantiopure isoxazole derivatives bearing one or two stereocenters.^[@cit8],[@cit9]^ However, the 4-nitro-5-styrylisoxazoles remained less explored substrates in stereoselective cascade reactions.^[@cit9d],[@cit9g]^ Very recently, Jørgensen\'s group utilized 4-nitro-5-styrylisoxazoles in trienamine-mediated asymmetric \[4+2\] cycloaddition reactions to afford cyclohexene products bearing three vicinal stereocenters.^[@cit10]^ Herein we report a novel cascade reaction involving a 1,4-/1,6-/vinylogous 1,2-addition sequence to access enantiopure cyclohexane rings bearing as many as six contiguous stereogenic centers, sequentially catalyzed by low loading of a cinchona derived squaramide^[@cit11]^ and an achiral base.

Initially, we started our investigation with a squaramide **I** (1 mol%) catalyzed one-pot three component reaction between ethyl acetoacetate (**1a**), β-nitrostyrene (**2a**) and 4-nitro-5-styrylisoxazole (**3a**) ([Table 1](#tab1){ref-type="table"}, entry 1). However our attempt to obtain the desired cyclohexane ring failed completely, and only the formation of the Michael adduct was observed.^[@cit12]^ We envisaged that the squaramide catalyst was not enough active to generate a nitronate anion in the corresponding Michael adduct to initiate a domino 1,6-/vinylogous 1,2-addition sequence. Thus, a sequential reaction was performed involving a squaramide **I** catalyzed Michael addition of the β-ketoester **1a** to the β-nitrostyrene **2a**, followed by the addition of **3a** and a catalytic amount of DBU (20 mol%) (entry 2). To our delight, the desired cyclohexane **4a** was obtained in 46% yield with excellent stereoselectivity (98% ee and \>20 : 1 dr). Further optimization of the reaction conditions by screening different solvents (entries 3--5) and bases (entries 6--11) showed that 30 mol% of DBU in CH~2~Cl~2~ provides a maximum yield of 62% and excellent stereoselectivity (entry 6). The use of a quinidine derived squaramide catalyst **II** led to the opposite enantiomer of the cyclohexane *ent*-**4a** with a similar yield, ee and dr (entry 12).

###### Optimizations of the reaction conditions[^*a*^](#tab1fna){ref-type="fn"}

  ![](c4cc09730k-u1.jpg){#ugr1}                                                                        
  ------------------------------------------ ----------------- ---------------- ------------- -------- ------------------------------------------
  1[^*e*^](#tab1fne){ref-type="table-fn"}    ---               CH~2~Cl~2~       24            ---      ---
  2                                          DBU (20)          CH~2~Cl~2~       24 + 24       46       98
  3                                          DBU (20)          CHCl~3~          24 + 24       35       98
  4                                          DBU (20)          Toluene          24 + 24       44       98
  5                                          DBU (30)          THF              24 + 24       36       98
  6[^*f*^](#tab1fnf){ref-type="table-fn"}    **DBU (30)**      **CH~2~Cl~2~**   **24 + 48**   **62**   **98**
  7[^*f*^](#tab1fnf){ref-type="table-fn"}    DBN (30)          CH~2~Cl~2~       24 + 48       36       97
  8[^*f*^](#tab1fnf){ref-type="table-fn"}    TEA (30)          CH~2~Cl~2~       24 + 48       Traces   n.d.
  9[^*f*^](#tab1fnf){ref-type="table-fn"}    TBD (30)          CH~2~Cl~2~       24 + 48       29       98
  10[^*f*^](#tab1fnf){ref-type="table-fn"}   DABCO (30)        CH~2~Cl~2~       24 + 48       ---      ---
  11[^*f*^](#tab1fnf){ref-type="table-fn"}   Piperidine (30)   CH~2~Cl~2~       24 + 48       Traces   n.d.
  12[^*f*^](#tab1fnf){ref-type="table-fn"}   DBU (30)          CH~2~Cl~2~       24 + 48       58       96[^*g*^](#tab1fng){ref-type="table-fn"}

^*a*^Reaction conditions: 0.2 mmol of **1a**, 0.2 mmol of **2a**, 1 mol% of **I**, 0.24 mmol of **3a** and *x* mol% of base (0.1 M in solvent).

^*b*^Time in hours for both reaction steps.

^*c*^Yield of isolated **4a** after column chromatography.

^*d*^Enantiomeric excess of the major diastereomer (\>20 : 1 dr) determined by HPLC analysis on a chiral stationary phase.

^*e*^All the reactants were added in one step.

^*f*^2 equivalents of **3a** were used.

^*g*^ee value of *ent*-**4a** synthesized by using catalyst **II**.

Once equipped with optimized reaction conditions, we evaluated the substrate scope at a 0.5 mmol scale of the β-dicarbonyl compounds and the β-nitrostyrenes ([Table 2](#tab2){ref-type="table"}). The various nitroalkenes bearing electron withdrawing and electron donating groups gave rise to the corresponding isoxazole products **4b--e** in 55--67% yield and excellent stereoselectivities (\>20 : 1 dr and 93--99% ee). The nitroalkenes bearing a heteroaromatic group also worked well in this cascade sequence to provide the desired product **4f** in 61% yield and 91% ee. Further screening of different 4-nitro-5-styrylisoxazoles bearing electron withdrawing and electron releasing substituents on the aryl ring as well as heteroaryl group provided a direct access to the corresponding cyclohexanes **4g--m** in good yields and high enantioselectivities (95--99% ee). The methyl acetoacetate and acetyl acetone were also tolerated under this one-pot protocol to give rise to the respective products **4n** and **4o** in good yields and excellent stereoselectivities. Employing a pseudo-enantiomeric amino-squaramide catalyst **II** successfully led to the formation of the enantiomers of **4a--f**, **4h** and **4l** in very good yields (51--69%) and again excellent asymmetric inductions (\>20 : 1 dr and 95--98% ee).

###### Substrate scope[^*a*^](#tab2fna){ref-type="fn"}

  ![](c4cc09730k-u2.jpg){#ugr2}                                              
  ------------------------------- ----- --------------- --------------- ---- ----
  **4a**                          OEt   Ph              Ph              61   98
  **4b**                          OEt   4-FC~6~H~4~     Ph              64   99
  **4c**                          OEt   4-ClC~6~H~4~    Ph              55   99
  **4d**                          OEt   4-MeC~6~H~4~    Ph              63   93
  **4e**                          OEt   4-MeOC~6~H~4~   Ph              67   97
  **4f**                          OEt   2-Thienyl       Ph              61   91
  **4g**                          OEt   Ph              4-FC~6~H~4~     60   98
  **4h**                          OEt   Ph              4-ClC~6~H~4~    61   97
  **4i**                          OEt   Ph              3-ClC~6~H~4~    69   97
  **4j**                          OEt   Ph              4-MeC~6~H~4~    73   99
  **4k**                          OEt   Ph              2-MeC~6~H~4~    49   95
  **4l**                          OEt   Ph              4-MeOC~6~H~4~   39   96
  **4m**                          OEt   Ph              2-Thienyl       50   97
  **4n**                          OMe   Ph              Ph              58   97
  **4o**                          Me    Ph              Ph              50   96
  *ent*-**4a**                    OEt   Ph              Ph              69   96
  *ent*-**4b**                    OEt   4-FC~6~H~4~     Ph              63   97
  *ent*-**4c**                    OEt   4-ClC~6~H~4~    Ph              51   95
  *ent*-**4d**                    OEt   4-MeC~6~H~4~    Ph              64   98
  *ent*-**4e**                    OEt   4-MeOC~6~H~4~   Ph              66   95
  *ent*-**4f**                    OEt   2-Thienyl       Ph              59   96
  *ent*-**4h**                    OEt   Ph              4-ClC~6~H~4~    60   97
  *ent*-**4k**                    OEt   Ph              2-MeC~6~H~4~    50   96

^*a*^Reaction conditions: 0.5 mmol of **1**, 0.5 mmol of **2**, 1 mol% of **I** (entry 1--17) or **II**, 1.0 mmol of **3** and 30 mol% of DBU (0.1 M in CH~2~Cl~2~).

^*b*^Yield of isolated product after column chromatography.

^*c*^Enantiomeric excess of the major diastereomer determined by HPLC analysis on a chiral stationary phase.

The absolute configuration of the products **4a--o** can be assigned as (1*S*), (2*S*), (3*R*), (4*S*), (5*S*) and (6*R*) on the basis of the X-ray crystallographic analysis of **4a** ([Fig. 2](#fig2){ref-type="fig"}).^[@cit13]^ Click here for additional data file. Click here for additional data file.

![X-ray structure of **4a**.](c4cc09730k-f2){#fig2}

To demonstrate the practical and preparative application of this new organocascade 1,4-/1,6-/1,2-addition sequence, we performed a gram-scale reaction between **1a**, **2a** and **3a** using a lower loading (0.5 mol%) of the squaramide **I** ([Scheme 2](#sch2){ref-type="fig"}). The desired product **4a** was obtained in 57% yield with unchanged ee and dr values. The enantiomeric purity could be enriched to \>99% ee after a single crystallization of the product.

![Gram-scale 1,4-/1,6-/1,2-addition sequence.](c4cc09730k-s2){#sch2}

In conclusion, we have developed a novel 1,4-/1,6-/1,2-addition cascade sequence catalyzed sequentially by low loading of a cinchona-derived squaramide and a commercially available achiral base to afford a series of highly substituted cyclohexane derivatives bearing six consecutive stereogenic centers in good yields and excellent stereoselectivities. The enantiomeric cyclohexanes are also easily synthesized on a same level of asymmetric induction by employing a pseudo-enantiomeric squaramide catalyst. A successful gram-scale reaction documents the preparative utility of this organocascade protocol.
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[^1]: †Electronic supplementary information (ESI) available. CCDC [1037530](1037530). For ESI and crystallographic data in CIF or other electronic format see DOI: [10.1039/c4cc09730k](10.1039/c4cc09730k)
